Key facts
- This page summarizes Chaitan Khosla PhD's Form 4 filing for Entero Therapeutics, Inc. (ENTO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 12 Jun 2024, 18:23.
Chaitan Khosla PhD - 11 Jun 2024 Form 4 Insider Report for Entero Therapeutics, Inc. (ENTO)
- Reporting relationship
- Director
- Issuer ticker
- ENTO
- Reported as of
- 11 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Jun 2024, 18:23:05 UTC
- Prior SEC filing
- 15 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sarah Romano, Attorney-in-Fact for Chaitan Khosla
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Chaitan Khosla PhD filed Form 4 for Entero Therapeutics, Inc. (ENTO) on 12 Jun 2024.
Change
- Previous filing in this sequence was filed on 15 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ENTO
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +24,889
- Change %
- Price
- $0.000000
- Shares after
- 24,889
- Date
- 11 Jun 2024
- Ownership
- Direct
- Footnotes
- F1, F2
ENTO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 440
- Date
- 11 Jun 2024
- Ownership
- See footnote
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
On June 11, 2024, the Reporting Person was granted 24,889 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest in three equal increments on July 1, 2024, September 30, 2024, and December 31, 2024.
Footnote F2
Includes unvested RSUs.
Footnote F3
Held directly by the Chaitan Khosla Living Trust, in which the Reporting Person serves as the sole Trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.